scholarly journals Pivotal role of paracrine effects in stem cell therapies in regenerative medicine: can we translate stem cell-secreted paracrine factors and microvesicles into better therapeutic strategies?

Leukemia ◽  
2011 ◽  
Vol 26 (6) ◽  
pp. 1166-1173 ◽  
Author(s):  
M Z Ratajczak ◽  
M Kucia ◽  
T Jadczyk ◽  
N J Greco ◽  
W Wojakowski ◽  
...  
Keyword(s):  
Stem Cell ◽  
Regenerative Medicine ◽  
Therapeutic Strategies ◽  
Pivotal Role ◽  
Stem Cell Therapies ◽  
Paracrine Factors ◽  
Paracrine Effects ◽  
Cell Therapies

Endometrial Regeneration in Asherman's Syndrome: Clinical and Translational evidence of Stem Cell Therapies

2019 ◽  
Vol 14 (6) ◽  
pp. 454-459
Author(s):  
Xuejing Hou ◽  
Ying Liu ◽  
Isabelle Streuli ◽  
Patrick Dällenbach ◽  
Jean Dubuisson ◽  
...  
Keyword(s):  
Stem Cell ◽  
Molecular Mechanisms ◽  
Uterine Cavity ◽  
Stem Cell Therapies ◽  
Intrauterine Adhesions ◽  
Asherman’S Syndrome ◽  
Cell Therapies ◽  
Fibrotic Process ◽  
Physical Barriers

Asherman’s Syndrome or Intrauterine adhesions is an acquired uterine condition where fibrous scarring forms within the uterine cavity, resulting in reduced menstrual flow, pelvic pain and infertility. Until recently, the molecular mechanisms leading to the formation of fibrosis were poorly understood, and the treatment of Asherman’s syndrome has largely focused on hysteroscopic resection of adhesions, hormonal therapy, and physical barriers. Numerous studies have begun exploring the molecular mechanisms behind the fibrotic process underlying Asherman’s Syndrome as well as the role of stem cells in the regeneration of the endometrium as a treatment modality. The present review offers a summary of available stem cell-based regeneration studies, as well as highlighting current gaps in research.

The Combination of Light and Stem Cell Therapies: A Novel Approach in Regenerative Medicine

2010 ◽  
Author(s):  
Juanita Anders ◽  
Helina Moges ◽  
Xingjia Wu ◽  
Ilko Ilev ◽  
Ronald Waynant ◽  
...  
Keyword(s):  
Stem Cell ◽  
Regenerative Medicine ◽  
Stem Cell Therapies ◽  
Cell Therapies ◽  
Novel Approach

scholarly journals Endothelial-Mesenchymal Transition in Regenerative Medicine

2016 ◽  
Vol 2016 ◽  
pp. 1-7 ◽  
Author(s):  
Damian Medici
Keyword(s):  
Stem Cell ◽  
Degenerative Diseases ◽  
Connective Tissues ◽  
Stem Cell Therapies ◽  
Cell Therapies ◽  
Mesenchymal Transition ◽  
Signaling Mechanisms ◽  
Recent Developments ◽  
Endothelial Mesenchymal Transition

Endothelial-mesenchymal transition (EndMT) is a fundamental cellular mechanism that regulates embryonic development and diseases such as cancer and fibrosis. Recent developments in biomedical research have shown remarkable potential to harness the EndMT process for tissue engineering and regeneration. As an alternative to traditional or artificial stem cell therapies, EndMT may represent a safe method for engineering new tissues to treat degenerative diseases by mimicking a process that occurs in nature. This review discusses the signaling mechanisms and therapeutic inhibitors of EndMT, as well as the role of EndMT in development, disease, acquiring stem cell properties and generating connective tissues, and its potential as a novel mechanism for tissue regeneration.

A RAT by Another Name: 21st Century Cures Act and Stem Cell Therapies

2018 ◽  
Vol 44 (2-3) ◽  
pp. 291-308 ◽  
Author(s):  
Margaret F. Riley
Keyword(s):  
Stem Cell ◽  
Regenerative Medicine ◽  
Drug Administration ◽  
21St Century ◽  
Food And Drug Administration ◽  
Regulatory Framework ◽  
Stem Cell Therapies ◽  
Cell Therapies ◽  
21St Century Cures Act

Regenerative medicine (“RM”) is a 21st century technology whose regulation has badly needed a 21st century cure. It is not clear that the 21st Century Cures Act (“Cures Act”) is that cure, but it has not been a poison. For some months prior to the passage of the Cures Act it seemed that it might be a catalyst for really endangering the field by allowing a flood of untested therapies to continue to enter the market. That, fortunately, did not happen. Thus far, the Cures Act has been a useful tonic; its effect on RM has been largely symbolic. But it has allowed the Food and Drug Administration (“FDA”) to redirect resources, and it demanded the quick adoption of guidance. That has allowed the Agency to finalize a regulatory framework that has been sorely needed. The evidentiary flexibility within the Cures Act is extremely important for the development of technologies that do not fit easily into the traditional approval rubric.

Sign in / Sign up

Export Citation Format

Share Document